Navigation Links
Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer

For patients with high-risk breast cancer treated with radical mastectomy and adjuvant chemotherapy, the addition of radiation therapy leads to better survival outcomes with few long-term toxic effects, according to a 20-year follow-up of a randomized trial, which appears in the January 19 issue of the Journal of the National Cancer Institute.

The British Columbia randomized radiation therapy trial was designed to determine the effect on survival of the addition of locoregional radiation therapy (radiation to the lymph nodes and chest wall) to a course of chemotherapy after radical mastectomy in premenopausal women with lymph node–positive breast cancer. Between 1979 and 1986, 318 patients were randomly assigned to receive no radiation therapy or to receive radiation. A 15-year follow-up found that radiation therapy was associated with improved breast cancer survival but not with overall survival.

In this 20-year follow-up of the British Columbia trial, Joseph Ragaz, M.D., of McGill University Health Center in Montreal, and colleagues found that the chemotherapy and radiation regimen, compared with chemotherapy alone, was associated with improvement in all end points analyzed. This included a 32% reduction in breast cancer mortality and a 27% reduction in overall mortality compared with chemotherapy alone. In addition, long-term toxic effects, including cardiac deaths, were acceptable for both groups of patients.

"Our results, and those from other groups, confirm that in situations where residual disease remains, adjuvant chemotherapy alone in high-risk breast cancer patients is suboptimal and that the addition of locoregional radiation therapy is important to achieve the highest cure rate," the authors write.

In an editorial, Timothy Whelan, B.M., B.Ch., and Mark Levine, M.D., of the Juravinski Cancer Centre in Hamilton, Ontario, discuss the use of locoregional radiation therapy in breast cancer patients and note that fewer clinicians accept its use in moderate-risk patients. "Because uncertainties continue about the effectiveness of locoregional radiation therapy after mastectomy in moderate-risk patients, we strongly urge that a randomized controlled trial be mounted to resolve these uncertainties," they write.


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Adding radiation decreases breast cancer recurrence
2. Duke Experiments Boost Radiations Cancer-Killing Effects
3. Radiation-killed bacteria vaccine induces broad immune response in mice
4. Radiation-armed robot rapidly destroys human lung tumors
5. Radiation after surgery doubles survival time for some lung cancer patients
6. Radiation therapy combo cures prostate cancer long-term
7. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
8. Gene Therapy For Parkinsons Disease Moves Forward In Animals
9. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
10. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
11. Discovery Promises Simpler Therapy for Sickle Cell Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology: